Current best evidence on prescribed drugs

Pills
Drugdocs Logo

Current best evidence on prescribed drugs

Pills
HomeDrugsDRUGDOCS AIAboutNewsGlossaryContact
HomeDrugsAIAboutNewsGlossaryContact

DRUG ▾

ABCDEFGHIJKLMNOPQRSTUVWXYZ

DRUG

CLASS

AI

News

Cangrelor

(Kengreal®)

Cangrelor

Drug updated on 10/31/2024

Dosage FormInjection (intravenous; 50 mg/ 10 mL)
Drug ClassP2Y12 platelet inhibitors
Ongoing and
Completed Studies		ClinicalTrials.gov

Indication

  • Indicated as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients in who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
  • Cangrelor and Ticagrelor in STEMI (ST-elevated myocardial infarction) Patients: Cangrelor and ticagrelor demonstrated similar efficacy profiles in patients with STEMI undergoing percutaneous coronary intervention, showing no significant differences in high platelet reactivity, thrombosis risk, all-cause mortality, or bleeding incidence.
  • Neuroendovascular and Endovascular Procedures: Cangrelor showed favorable outcomes in neuroendovascular procedures, with 44% of patients achieving a modified Rankin Scale (mRS) score of 0-2 at 90 days and an intraprocedural thromboembolic complication rate of 8%. In large-vessel-occlusion stroke patients undergoing endovascular therapy, cangrelor achieved a successful reperfusion rate of 90.9% and a favorable mRS outcome in 51.2% of cases.
  • Safety Profile of Cangrelor in STEMI and Neuroendovascular Procedures: Cangrelor demonstrated a similar bleeding risk compared to ticagrelor in STEMI patients undergoing percutaneous intervention, with no significant differences in bleeding events observed between these two drugs. In neuroendovascular procedures, cangrelor was associated with low rates of bleeding, including a 6% incidence of symptomatic intracranial hemorrhage and 3% rates for both major extracranial and gastrointestinal bleeding.
  • Comparison of Bleeding Risks: Compared to clopidogrel, cangrelor showed a higher risk of minor bleeding events, while prasugrel was associated with an increased risk of both major and minor bleeding when compared to cangrelor, clopidogrel, and ticagrelor.
  • There is no population types or subgroups information available in the reviewed studies.